03:36 , Jan 4, 2019 |  BC Innovations  |  Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
02:23 , Jun 30, 2018 |  BioCentury  |  Product Development

Defining access potential - before it’s too late

We see it everywhere: confirmation bias. Innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. But confirmation bias is particularly problematic thanks...
23:34 , Jan 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Unexpected combinations

Two studies are prompting a rethink of how combination therapies target cancer at both the level of individual cells, and across a patient population. The papers are pushing drug developers to parse data from preclinical...
00:43 , Dec 22, 2017 |  BC Innovations  |  Strategy

Computing towards a cure

With the help of IBM, the Huntington’s disease not-for-profit CHDI and its partners have been bringing artificial intelligence to HD research and developing models of disease progression that integrate data from the level of genes...
18:12 , Dec 1, 2017 |  BioCentury  |  Finance

Blue skies for Codiak

EcoR1 opted to join Codiak BioSciences Inc.’s series C round based on the track record of the biotech’s team and the broad utility of its exosome therapeutics platform. The deal aims to get the company...
16:46 , Oct 20, 2017 |  BioCentury  |  Emerging Company Profile

One-upping c-MET

With a plethora of c-MET inhibitors in the clinic for cancer and two on the market, Octimet Oncology N.V. is banking on the dual selectivity of its molecule and its algorithm for identifying responders to...
20:34 , Jul 14, 2017 |  BioCentury  |  Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Plethora, Regent Pacific Group Ltd. deal

Urological disorder company Plethora said it and biopharma investment group Regent Pacific had reached “in principle” a deal whereby Regent would acquire the 70.12% of Plethora it does not already own. Plethora shareholders will receive...